Carcinosarcoma Clinical Trial
Official title:
Stereotactic Pelvic Adjuvant Radiation Therapy in Cancers of the Uterus: A Phase 1 Pilot Study (SPARTACUS)
Advanced technology has enabled radiation oncologists to more accurately and precisely target radiation to areas at risk while maximally sparing healthy tissue. Furthermore, there is growing evidence demonstrating both safety and efficacy for SBRT. We propose that these advantages are translatable to the adjuvant treatment of endometrial cancer. We submit that a prescription dose of 30 Gy in 5 fractions, which equates to a 2 Gy equivalent dose (i.e an EQD2) (α/β = 10 Gy) of 48 Gy, compares favorably to the EQD2 delivered standardly for adjuvant treatment (44.25 Gy via 45Gy/25Fx; 50 Gy at vaginal surface for vault brachytherapy) and therefore should be effective and safe dose in the adjuvant setting. Through precision delivery and careful dosimetry the treatment should be safe and well tolerated with minimal impact on patient quality of life.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04122872 -
GISAR German Interdisciplinary Sarcoma Registry
|
||
Recruiting |
NCT05265793 -
Camrelizumab Combined With Apatinib in the Treatment of Advanced Sarcomatoid Carcinoma or Carcinosarcoma
|
Phase 2 | |
Active, not recruiting |
NCT03570437 -
Does Cediranib With Paclitaxel, or Cediranib and Olaparib, Treat Advanced Endometrial Cancer Better Than Paclitaxel?
|
Phase 2 | |
Completed |
NCT03395080 -
A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer or Carcinosarcoma
|
Phase 2 | |
Completed |
NCT00815945 -
Multicenter Trial With PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors
|
Phase 2 | |
Withdrawn |
NCT03933761 -
Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or Chemotherapy
|
Phase 2 | |
Terminated |
NCT04688749 -
Use of Electrical Impedance Spectroscopy (EIS) for Early Diagnosis of Skin Damage
|
||
Completed |
NCT03241745 -
A Study of Nivolumab in Selected Uterine Cancer Patients
|
Phase 2 | |
Completed |
NCT04513665 -
ZW25 in Women With Endometrial Cancers
|
Phase 2 | |
Recruiting |
NCT05252416 -
(VELA) Study of BLU-222 in Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Available |
NCT04681248 -
Expanded Access Use of DKN-01 for the Treatment of Advanced Solid Tumors
|